Refine by
Solid Tumor Equipment & Supplies
237 equipment items found
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
ERBB inhibitor for Solid Tumors PHASE ...
by:Biozol GmbH based inEching,, GERMANY
contains DAPI nuclear staining dye, fluorescence mounting medium, no background autofluorescence, slowly hardening over weeks, strong reduction of photobleaching, viscous fluid, water-based ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
S6K, AKT, RSK inhibitor for Solid Tumors PHASE ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
Using its iSORT platform, T-Cure identified 806TCR, an NY-ESO-1-specific TCR restricted to HLA-A2 haplotype. The 806TCR is in IND-enabling studies. NY-ESO-1 has been demonstrated clinically as a suitable target for TCR therapies for multiple solid tumors. T-Cure is currently exploring partnerships in developing “off-the-shelf” approaches to utilize this all natural but high affinity ...
Manufactured by:The Menarini Group based inFlorence, ITALY
SL-901 is an oral small molecule PI3K and DNA-PK inhibitor that has demonstrated activity against PI3K α/δ and PIK3C2 β. SL-901 has shown preclinical activity against a variety of tumor types. A Phase 1 trial in patients with solid tumors is currently ...
by:AbelZeta Inc. based inRockville, MARYLAND (USA)
PRODUCT: C-CAR036. INDICATION: Solid Tumor. PLATFORM: CAR-T. PRECLINICAL: Claudin 18.2. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: Descriptor iNK cells [other CAR targets / dual ...
by:AbelZeta Inc. based inRockville, MARYLAND (USA)
PRODUCT: C-CAR031. INDICATION: HCC. PLATFORM: CAR-T. PRECLINICAL: GPC3. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: iT cells and macrophages [CARs+/- gene KOs]. ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: CAR iNK cells + novel receptor fusion proteins. ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-400, our DeltEx Allo DRI, is a preclinical product candidate expanding the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or “off-the-shelf” DeltEx DRI therapy. We aim to take the clinical results from the ongoing INB-200 and INB-100 clinical trials to provide the safety data to support an IND submission for INB-400. The ...
by:Genmab A/S based inCopenhagen V, DENMARK
DuoBody-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent ...
Manufactured by:PharmAbcine Inc. based inYuseong-gu, SOUTH KOREA
PMC-402 is a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization of Tie2 expressing macrophages, resulting in T cell activation. It binds to TIE2 expressing macrophages that activate T cells in the tumor microenvironment ...
by:Astraveus based inParis, FRANCE
Macrophages are versatile cells. They exhibit abilities to survive solid tumor microenvironment, to trigger inflammation and to absorb and digest debris or infected cells. CAR-Macrophages (CAR-M) are artificially directed against a cancerous target by a chimeric antigen receptor. CAR-M are still in their clinical infancy, however specific abilities of macrophages make them a promising approach to ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. It was granted IND approvals to be evaluated in clinical trials in China and the United States. It demonstrated favorable safety and tolerability profile in a prospective, open-label, dose-escalation Phase 1 clinical study (HLX07FIH, ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES028 is a potential first-in-class SIRPα/CLDN18.2 bsAb developed using our Bispecific Macrophage Engager (BiME®) platform. The SIRPα antibody blocks the “don’t-eat-me” signal while the TAA antibody provides an “eat-me” signal through Fc receptor engagement. ES028 and the BiME platform are designed for potent activation of phagocytosis and directly ...
Manufactured by:Theriva Biologics, Inc., formely known as ynthetic Biologics, Inc. based inRockville, MARYLAND (USA)
Solid tumors are complex organ-like structures consisting of cancer cells, vasculature, and tumor matrix. This dense extracellular matrix, also known as stroma, hampers the intratumoral accessibility of chemotherapy, antitumor immune cells, and oncolytic viruses. Our viruses are “armed” with a soluble version of human sperm hyaluronidase (hyal) PH20 to enhance virus spreading and help ...
Manufactured by:Alpinion Medical Systems Co., Ltd. based inAnyang-si, SOUTH KOREA
The VIFU 2000 is ALPINION’s pre-clinical HIFU (High Intensity Focused Ultrasound) system uniquely designed for investigating a wide range of HIFU applications in small animals. Embedded ALPINION’s proprietary HIFU technology and imaging technologies, the VIFU 2000 enables users to research ultrasound meditated drug delivery study, ablation for solid tumor, mechanical and cavitation ...
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
The proprietary ROCK platform enables a tumor-targeted approach that can be tailored across hematological and solid tumors. The ROCK (Redirected Optimized Cell Killing) platform allows for a modular approach to generating customizable ICE (innate cell engager) molecules. High-affinity ICE (innate cell engager) molecules, which are created using the ROCK platform, are capable of bivalent NK-cell ...
Manufactured by:PharmAbcine Inc. based inYuseong-gu, SOUTH KOREA
PMC-309 is an engineered monoclonal antibody that targets the negative immune checkpoint human VISTA (V-domain Ig suppressor of T cell activation). It indirectly promotes T cells' immune responses by inhibiting VISTA-expressing immunosuppressive cells such as MDSCs (Myeloid-Derived Suppressor Cells) which suppress T cell inactivation and ...